Amarin Chairman & CEO Issue Letter to Shareholders - Seite 2

Looking ahead, we believe we have established a strong foundation to drive shareholder value in 2024 and beyond:

• In the U.S., we will focus on extending IPE market leadership, where we have maintained a 57% market share, including plans to launch an authorized generic if required.
• In Europe, we will focus on accelerating revenues in key markets like Spain and the U.K., and plans are in place for pricing and reimbursement submissions in Italy, France and Germany.
• In the RoW, we are focused on shifting from partnerships to implementing plans to support our partners advance market access and commercialization for VASCEPA/VAZKEPA.
  

We thank all our fellow shareholders for your patience and continued support.

Sincerely,
Odysseas Kostas, M.D.
Chairman, Amarin Board of Directors

Patrick Holt
President & CEO, Amarin

About Amarin  

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world.

Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including beliefs about Amarin’s key achievements in 2023 and the potential impact and outlook for achievements in 2024 and beyond; Amarin’s 2024 financial outlook and cash position; Amarin’s overall efforts to expand access and reimbursement to VAZKEPA across global markets; and the overall potential and future success of VASCEPA/VAZKEPA and Amarin generally. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including Amarin’s annual report on Form 10-K for the full year ended 2022. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate.